Gyre Therapeutics (GYRE) Receivables - Net (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Receivables - Net data on file, last reported at $26.6 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $26.6 million, up 29.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.6 million (up 29.36% YoY), and the FY2025 annual result was $31.2 million, up 57.74% from the prior year.
• Receivables - Net fell to $26.6 million in Q1 2026 per GYRE's latest filing, from $31.2 million in the prior quarter.
• Over five years, Receivables - Net peaked at $31.2 million in Q4 2025 and troughed at $564000.0 in Q1 2022.
• A 5-year average of $16.6 million and a median of $18.6 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net tumbled 43.94% in 2022, then jumped 786.52% in 2023.
• A 5-year view of Receivables - Net shows it stood at $15.7 million in 2022, then decreased by 3.65% to $15.2 million in 2023, then soared by 30.57% to $19.8 million in 2024, then soared by 57.74% to $31.2 million in 2025, then declined by 14.89% to $26.6 million in 2026.
• Business Quant data shows GYRE's Receivables - Net at $26.6 million in Q1 2026, $31.2 million in Q4 2025, and $26.1 million in Q3 2025.